Table 1 Patient characteristics, n = 100
From: 30-day mortality in patients treated for brain metastases: extracranial causes dominate
Baseline parameter | Number (= %) |
|---|---|
Sex | |
Female sex | 46 |
Male sex | 54 |
Tumor type | |
Non-small cell lung cancer | 42 |
Breast cancer, triple negative | 3 |
Breast cancer, Her2 positive | 4 |
Breast cancer, other | 4 |
Malignant melanoma | 12 |
Small cell lung cancer | 9 |
Renal cell cancer | 8 |
Colorectal cancer | 10 |
Other gastrointestinal cancer | 5 |
Other primary tumors (bladder, head/neck) | 3 |
Extracranial disease | |
No extracranial metastases | 9 |
Extracranial metastases | 91 |
Bone metastases | 37 |
Liver metastases | 38 |
Lung/pleura metastases | 56 |
Controlled primary tumor | 55 |
Uncontrolled primary tumor* | 45 |
Active organ sites incl. uncontrolled primary tumor: 0 | 5 |
Active sites: 1** | 16 |
Active sites: 2 | 25 |
Active sites: 3 | 31 |
Active sites: 4 | 17 |
Active sites: > 4 | 6 |
Brain metastases | |
Single brain metastasis | 12 |
Two or three brain metastases | 21 |
Four or five brain metastases | 19 |
Six to ten brain metastases | 27 |
More than ten brain metastases | 21 |
Synchronous brain metastases | 24 |
Metachronous brain metastases, within 12 months | 37 |
Metachronous brain metastases, 13–24 months | 11 |
Metachronous brain metastases, 25–36 months | 11 |
Metachronous brain metastases, 37–60 months | 8 |
Metachronous brain metastases, > 60 months | 9 |
Asymptomatic brain metastases | 9 |
Symptom response to steroids | 64 |
No response to steroids | 27 |
Largest lesion diameter ≤ 2 cm | 48 |
Largest lesion diameter 2.1–3.0 cm | 23 |
Largest lesion diameter 3.1–4.0 cm | 19 |
Largest lesion diameter > 4.0 cm | 10 |
Karnofsky performance status (KPS) | |
KPS 50 | 14 |
KPS 60 | 30 |
KPS 70 | 44 |
KPS 80 | 8 |
KPS 90 | 4 |
Treatment | |
Primary systemic treatment | 7 |
Surgery with post-operative cavity radiotherapy | 2 |
Stereotactic single fraction radiosurgery | 6 |
Stereotactic fractionated radiotherapy | 6 |
Whole-brain radiotherapy, 20 Gy in 5 fractions | 12 |
Whole-brain radiotherapy, 30 Gy in 10 fracions | 64 |
Whole-brain radiotherapy, higher dose than 30 Gy | 3 |
Any systemic therapy after diagnosis of brain metastases | 34 |
Age, years | |
< 60 | 18 |
60–69 | 40 |
70–79 | 35 |
80–89 | 5 |
≥ 90 | 2 |
Extracranial score (EC-S; LDH, albumin, extracranial involvement of at least 2 organs, e.g. bone + liver) | |
All 3 adverse factors present | 9 |
Two of these factors present | 42 |
One of these factors present | 36 |
No adverse factors present | 13 |
LabBM score (5 blood test results) | |
LabBM score 0 (favorable) | 15 |
LabBM score 0.5 | 7 |
LabBM score 1.0 | 17 |
LabBM score 1.5 | 21 |
LabBM score 2.0 | 14 |
LabBM score 2.5 | 15 |
LabBM score 3.0 | 9 |
LabBM score 3.5 | 2 |